Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Alignment Healthcare Inc ha un obiettivo di prezzo di consenso pari a $16.18, stabilito in base alle ultime valutazioni degli analisti di 15. Le ultime 3 valutazioni degli analisti sono state rilasciate da Keybanc, Barclays y UBS il agosto 25, 2025, julio 31, 2025 y mayo 2, 2025. Con un obiettivo di prezzo medio di $17 tra le Keybanc, Barclays y UBS, c'è un implicito -2.19% downside per Alignment Healthcare Inc da queste valutazioni degli analisti.
1calculado a partir de las calificaciones de los analistas
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
08/25/2025 | 20.83% | Keybanc | → $21 | Upgrade | Sector Weight → Overweight | |||
07/31/2025 | -25.2% | Barclays | $9 → $13 | Upgrade | Underweight → Equal-Weight | |||
05/02/2025 | -2.19% | UBS | $16 → $17 | Maintains | Neutral | |||
04/15/2025 | 26.58% | Baird | $17 → $22 | Maintains | Outperform | |||
04/08/2025 | 32.34% | Stifel | $18 → $23 | Maintains | Buy | |||
03/06/2025 | -2.19% | JP Morgan | $14 → $17 | Maintains | Neutral | |||
03/04/2025 | 20.83% | Piper Sandler | $14 → $21 | Maintains | Overweight | |||
03/04/2025 | 6.44% | B of A Securities | $15.5 → $18.5 | Maintains | Buy | |||
02/28/2025 | 3.57% | Stifel | $16 → $18 | Maintains | Buy | |||
02/28/2025 | -48.22% | Barclays | $8 → $9 | Maintains | Underweight | |||
02/24/2025 | -2.19% | Stephens & Co. | $17 → $17 | Reiterates | Overweight → Overweight | |||
01/14/2025 | -7.94% | Stifel | $14 → $16 | Maintains | Buy | |||
01/02/2025 | -2.19% | Stephens & Co. | $17 → $17 | Reiterates | Overweight → Overweight | |||
12/03/2024 | -2.19% | Stephens & Co. | $13 → $17 | Upgrade | Equal-Weight → Overweight | |||
10/31/2024 | -25.2% | TD Cowen | $10 → $13 | Maintains | Buy | |||
10/30/2024 | -53.97% | Barclays | $7 → $8 | Maintains | Underweight | |||
10/30/2024 | -30.96% | UBS | $9 → $12 | Maintains | Neutral | |||
10/11/2024 | — | Keybanc | — | Initiates | → Sector Weight | |||
08/14/2024 | -36.71% | Baird | $10 → $11 | Maintains | Outperform | |||
08/06/2024 | -42.46% | TD Cowen | $8 → $10 | Maintains | Buy | |||
08/06/2024 | -42.46% | Piper Sandler | $8 → $10 | Reiterates | Overweight → Overweight | |||
08/05/2024 | -59.72% | Barclays | $4.5 → $7 | Maintains | Underweight | |||
07/26/2024 | -30.96% | Stifel | $9 → $12 | Maintains | Buy | |||
05/30/2024 | -42.46% | Baird | → $10 | Initiates | → Outperform | |||
05/08/2024 | -53.97% | Piper Sandler | $6 → $8 | Upgrade | Neutral → Overweight | |||
05/03/2024 | -59.72% | Stephens & Co. | $6 → $7 | Maintains | Equal-Weight | |||
04/23/2024 | -48.22% | Stifel | $11 → $9 | Maintains | Buy | |||
03/06/2024 | -65.48% | Piper Sandler | $12 → $6 | Downgrade | Overweight → Neutral | |||
03/06/2024 | -74.11% | Barclays | → $4.5 | Initiates | → Underweight | |||
02/28/2024 | -51.09% | UBS | $9 → $8.5 | Maintains | Neutral | |||
01/24/2024 | -36.71% | Stifel | → $11 | Initiates | → Buy | |||
01/09/2024 | -30.96% | Raymond James | $10 → $12 | Maintains | Strong Buy | |||
01/09/2024 | -39.59% | Stephens & Co. | $10 → $10.5 | Maintains | Equal-Weight | |||
12/21/2023 | -48.22% | UBS | $6.5 → $9 | Maintains | Neutral | |||
11/02/2023 | -58.29% | B of A Securities | → $7.25 | Downgrade | Buy → Neutral | |||
10/16/2023 | -42.46% | Raymond James | $9 → $10 | Upgrade | Outperform → Strong Buy | |||
10/12/2023 | -48.22% | Stephens & Co. | → $9 | Initiates | → Equal-Weight | |||
08/30/2023 | -30.96% | Morgan Stanley | $19 → $12 | Maintains | Overweight | |||
07/14/2023 | 9.32% | Morgan Stanley | $19 → $19 | Reiterates | Overweight → Overweight | |||
07/13/2023 | -65.48% | UBS | $8 → $6 | Maintains | Neutral | |||
07/07/2023 | -42.46% | JP Morgan | $12 → $10 | Maintains | Neutral | |||
05/01/2023 | -48.22% | Raymond James | → $9 | Upgrade | Market Perform → Outperform | |||
04/19/2023 | -30.96% | Goldman Sachs | $14 → $12 | Maintains | Buy | |||
03/03/2023 | -19.45% | Goldman Sachs | $21 → $14 | Maintains | Buy | |||
03/03/2023 | -30.96% | Piper Sandler | $19 → $12 | Maintains | Overweight | |||
03/02/2023 | -42.46% | TD Cowen | $17 → $10 | Maintains | Outperform | |||
02/23/2023 | -30.96% | JP Morgan | $22 → $12 | Downgrade | Overweight → Neutral | |||
11/21/2022 | — | Raymond James | — | Downgrade | Outperform → Market Perform |
El último precio objetivo de Alignment Healthcare (NASDAQ:ALHC) fue comunicado por Keybanc el agosto 25, 2025. La firma de analistas fijó un precio objetivo para $21.00 que espera ALHC a rise dentro de 12 meses (un posible 20.83% upside). 18 firmas de analistas han reportado calificaciones en el último año.
La última calificación de analistas para Alignment Healthcare (NASDAQ:ALHC) fue proporcionada por Keybanc, y Alignment Healthcare mejorado su overweight calificación.
La última revisión al alza de Alignment Healthcare Inc se produjo en agosto 25, 2025, cuando Keybanc elevó su precio objetivo a $21. Keybanc anteriormente tenía a sector weight para Alignment Healthcare Inc.
La última revisión a la baja de Alignment Healthcare Inc se produjo en marzo 6, 2024, cuando Piper Sandler cambió su precio objetivo de $12 a $6 para Alignment Healthcare Inc.
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Alignment Healthcare, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Alignment Healthcare se registró el agosto 25, 2025, por lo que la próxima calificación estará disponible en torno al agosto 25, 2026.
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Alignment Healthcare (ALHC) fue un mejorado con un precio objetivo de $0.00 a $21.00. El precio actual al que cotiza Alignment Healthcare (ALHC) es de $17.38, que es within del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.